CVE-2022-23469

Public Exploit
Authorization header displayed in the debug logs

Description

Traefik is an open source HTTP reverse proxy and load balancer. Versions prior to 2.9.6 are subject to a potential vulnerability in Traefik displaying the Authorization header in its debug logs. In certain cases, if the log level is set to DEBUG, credentials provided using the Authorization header are displayed in the debug logs. Attackers must have access to a users logging system in order for credentials to be stolen. This issue has been addressed in version 2.9.6. Users are advised to upgrade. Users unable to upgrade may set the log level to `INFO`, `WARN`, or `ERROR`.

Categories

3.5
CVSS
Severity: Low
CVSS 3.1 •
EPSS 0.28%
Third-Party Advisory github.com Third-Party Advisory github.com Third-Party Advisory github.com
Affected: traefik traefik
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2022-23469?
CVE-2022-23469 has been scored as a low severity vulnerability.
How to fix CVE-2022-23469?
To fix CVE-2022-23469, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2022-23469 being actively exploited in the wild?
It is possible that CVE-2022-23469 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2022-23469?
CVE-2022-23469 affects traefik traefik.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.